Clinical Research Advances in Chronic Lymphocytic Leukemia (CLL)

Dear Colleagues,

In recent years, chronic lymphocytic leukemia (CLL) treatments have altered dramatically. In the past, the frontline therapy for CLL was chemoimmunotherapy, which left many patients with treatment-limiting toxicities. This has changed to targeted therapies, employing, for example, Bruton tyrosine kinase (BTK) inhibitors such as Ibrutinib, and Bcl-2 inhibitors such as Venetoclax. These treatments enable more CLL patients to be treated, with longer remission periods. However, challenges remain, such as heart toxicities and drug resistance. Furthermore, many questions pertaining to how various treatment options may be tailored to the correct patient at the correct time remain unanswered. Beyond treatments, changes in patients’ immune systems and in the microenvironment of the bone marrow and lymph nodes are only now coming into focus. These microenvironments render CLL cells drug-resistant and allow for the proliferation of CLL cells. Understanding how CLL cells interact in these microenvironments and how treatments might be targeted are key questions for CLL researchers.

We are pleased to invite you to submit your high-quality manuscripts to this Special Issue. The aim of this Special Issue is to focus on clinical advances in CLL treatment and management, as well as changes in the microenvironment of CLL patients. We hope to gather a collection of at least 10 articles. Original research articles and reviews are welcome. We will also accept manuscripts presenting retrospective and prospective clinical observations.

Prof. Dr. Spencer Gibson
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.